Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
Herceptin patents knocked over
As the main patent on Roche's blockbuster breast cancer drug Herceptin heads towards patent expiry in Europe, Hospira has succeeded in having two further UK patents declared invalid.
Working Life
The sustainable commute to MSD
Imagine being paid to commute to work. As Karen Keast discovers, MSD employees receive incentive payments for choosing a sustainable commute to the pharmaco's new Sydney headquarters.
Approvals Action
New generics dominate ARTG changes
All action during the week was in the generic space with no new medicine registrations but a number of additions to molecules in anticipation of PBS listing post patent expiries.
Open Forum
Pre-Budget kite flying not much use to anyone
The amount of cost-focused kite-flying going on in the pre-Budget health debate has begun to alarm the many who would like to see a more sensible and less narrow policy discussion.